Skip to main content

Advertisement

ADVERTISEMENT

Volume 13 - Issue 11 - November 2016

News

News
10/31/2016
The FDA recently approved a new, more concentrated format of the high-dose bolus of the GP IIb/IIIa agent tirofiban (premixed, ready to use, at 250 mcg/mL in a 15 mL vial). Craig Walker, MD, answers questions about the use of GP IIb/IIIa...
The FDA recently approved a new, more concentrated format of the high-dose bolus of the GP IIb/IIIa agent tirofiban (premixed, ready to use, at 250 mcg/mL in a 15 mL vial). Craig Walker, MD, answers questions about the use of GP IIb/IIIa...
The FDA recently approved a new,...
10/31/2016
Vascular Disease Management

Insights

Interview
10/31/2016
The 1-year results from IN.PACT Global confirm safety and effectiveness of the In.Pact Admiral DCB in femoropopliteal lesions. Michael R. Jaff, DO, answers questions about the results and their implications for peripheral vascular therapy.
The 1-year results from IN.PACT Global confirm safety and effectiveness of the In.Pact Admiral DCB in femoropopliteal lesions. Michael R. Jaff, DO, answers questions about the results and their implications for peripheral vascular therapy.
The 1-year results from IN.PACT...
10/31/2016
Vascular Disease Management

Feature

Case Report
10/31/2016
The authors present a rare case of upper extremity PCD related to the presence of a peripherally inserted central catheter. Endovascular therapy was utilized in the form of acoustic-assisted catheter directed thrombolysis with complete...
The authors present a rare case of upper extremity PCD related to the presence of a peripherally inserted central catheter. Endovascular therapy was utilized in the form of acoustic-assisted catheter directed thrombolysis with complete...
The authors present a rare case...
10/31/2016
Vascular Disease Management
Clinical Review
10/31/2016
Limb salvage rates that are consistently superior to patency rates for CLI patients have prompted some to question whether perfusion really matters. The authors explore the discrepancy and find that the difference can be explained by several...
Limb salvage rates that are consistently superior to patency rates for CLI patients have prompted some to question whether perfusion really matters. The authors explore the discrepancy and find that the difference can be explained by several...
Limb salvage rates that are...
10/31/2016
Vascular Disease Management

Column

Editor's Corner
10/30/2016
The discrepancy between patency and limb salvage for patients with the most severe peripheral arterial disease has been the source of much debate. It is possible, however, that the discrepancy is not as wide as previously thought.
The discrepancy between patency and limb salvage for patients with the most severe peripheral arterial disease has been the source of much debate. It is possible, however, that the discrepancy is not as wide as previously thought.
The discrepancy between patency...
10/30/2016
Vascular Disease Management

Advertisement

Advertisement

Advertisement